Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 6
Submit an article Journal homepage
85
Views
18
CrossRef citations to date
0
Altmetric
Review

Drug delivery strategies for cathepsin inhibitors in joint diseases

Dong Wang Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-6025, USA. [email protected]
&
Dieter Brömme Faculty of Dentistry, University of British Columbia, Vancouver, V6T 1Z3, Canada
Pages 1015-1028 | Published online: 04 Nov 2005

Bibliography

  • OKADA Y: Proteinases and matrix degradation. In: Kelley's Textbook of Rheurnatology (Volume 1). ED H RC B GS F MC G JS S S R CB Sledge (Eds), Elsevier Saunders, Philadelphia, PA, USA (2005):63–81.
  • •A good summary of proteinases involved in Joint diseases.
  • WANG D, LI W, PECHAR M, KOPECKOVA P, BROMME D, KOPECEK J: Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis. Lit. Pharm. (2004) 277:73–79.
  • GOLDRING SR, GOLDRING MB: Biology of normal joint. In: Kelley's Textbook of Rheumatology (Volume 1). ED H RC B GS F MC G JS S S R CB Sledge (Eds), Elsevier Saunders, Philadelphia, PA, USA (2005):1–34.
  • ••An excellent review of joint biology.
  • ALVAREZ-LORENZO C, CONCHEIRO A, DUBOVIK AS, GRINBERG NV, BUROVA TV, GRINBERG VY: Temperature-sensitive chitosan-poly(N-isopropylacrylamide) interpenetrated networks with enhanced loading capacity and controlled release properties. ./. Control. Release (2005) 102:629–641.
  • DELMAS PD: Biochemical markers of bone turnover in Paget's disease of bone. I Bone Miner. Res. (1999) 14(Suppl.):66–69.
  • REIJMAN M, HAZES JM, BIERMA-ZEINSTRA SM et al.: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. (2004) 50:2471–2478.
  • KIANI C, CHEN L, WU YJ, YEE AJ, YANG BB: Structure and function of aggrecan. Cell Res. (2002) 12:19–32.
  • O'DELL JR: Therapeutic strategies for rheumatoid arthritis. N Engl. I Med. (2004) 350:2591–2602.
  • FIRESTEIN GS: Etiology and pathogenesis of rheumatoid arthritis. In: Kelley's Textbook of Rheumatology (Volume 2). ED H RC B GS F MC G JS S S R CB Sledge (Eds), Elsevier Saunders, Philadelphia, PA, USA (2005):996–1042.
  • •A good review of RA.
  • MCDUFFIE FC: Morbidity impact of rheumatoid arthritis in society. Am. .1 Med. (1985) 78:1–5.
  • TAK PP, BREEDVELD FC: Current perspectives on synovitis. Arthritis Res. (1999) 1:11–16.
  • SMOLEN JS, STEINER G: Therapeutic strategies for rheumatoid arthritis. Nat. Rev Drug Discov. (2003) 2:473–488.
  • ••A very interesting review mainly coveringDMARDs.
  • FITZGERALD GA: COX-2 and beyond:approaches to prostaglandin inhibition in human disease. Nat. Rev Drug Discov. (2003) 2:879–890.
  • ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1125–1127.
  • WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J. Med. (1999) 340:253–259.
  • WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35–45.
  • BARNES PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Li. (1998) 94:557–572.
  • BADLEY EM, WANG PP: Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. Rheumatol (1998) 25:138–144.
  • WIELAND HA, MICHAELIS M, KIRSCHBAUM BJ, RUDOLPHI KA: Osteoarthritis - an untreatable disease? Nat. Rev Drug Discov. (2005) 4:331–344.
  • ••A very good review on OA and availabletreatment.
  • MOULTON PJ: Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br. J. Biomed. Sci. (1996) 53:317–324.
  • MURPHY G, KNAUPER V, ATKINSON S et al: Matrix metalloproteinases in arthritic disease. Arthritis Res. (2002) 4:S39–S49.
  • HOU WS, LI Z, GORDON RE et al: Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am. J. Pathol (2001) 159:2167–2177.
  • HASHIMOTO Y, KAKEGAWA H, NARITA Y et al.: Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem. Biophys. Res. Commun. (2001) 283:334–339.
  • HOU WS, LI W, KEYSZER G et al: Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. (2002) 46:663–674.
  • ••Very important paper about cathepsins Sand K and their role in arthritis.
  • KONTTINEN YT, MANDELIN J, LI TF et al.: Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. (2002) 46:953–960.
  • •Report regarding low pH in OA joints.
  • LI Z, YASUDA Y, LI W et al: Regulationof collagenase activities of human cathepsins by glycosaminoglycans. J. Biol. Chem. (2004) 279:5470–5479.
  • BROMME D, OKAMOTO K, WANG BB, BIROC S: Human cathepsin 02, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin 02 in Spodoptera frugiperda and characterization of the enzyme. J. Biol. Chem. (1996) 271:2126–2132.
  • SEEMAYER CA, KUCHEN S, KUENZLER P et al.: Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis. Am. Pathol (2003) 162:1549–1557.
  • SAEGUSA K, ISHIMARU N, YANAGI K et al: Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. ./. Clin. Invest. (2002) 110:361–369.
  • REDDY VY, ZHANG QY, WEISS SJ: Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc. Natl. Acad. Li. USA (1995) 92:3849–3853.
  • EVERTS V, VAN ZEE E, CREEMERS L, BEERTSEN W: Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem. J. (1996) 28:229–245.
  • YASUDA Y, KALETA J, BROMME D: The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deily. Rev (2005) 57:973–993.
  • BRINCKERHOFF C: Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum. (1991) 34:1073–1075.
  • GORDON JL, DRUMMOND AH, GALLOWAY WA: Metalloproteinase inhibitors as therapeutics. Clin. Exp. Rheumatol (1993) 11:S91–S94.
  • MENTZEL K, BRAUER R: Matrix metalloproteinases, IL-6, and nitric oxide in rat antigen-induced arthritis. Clin. Exp. Rheumatol (1998) 16:269–276.
  • BURLEIGH MC, BARRETT AJ, LAZARUS GS: Cathepsin Bl. A lysosomal enzyme that degrades native collagen. Biochem. 1 (1974) 137:387–398.
  • KIRSCHKE H, KEMBHAVI AA, BOHLEY P, BARRETT AJ: Action of rat liver cathepsin L on collagen and other substrates. Biochem. J. (1982) 201:367–372.
  • GARNERO P, BOREL 0, BYRJALSEN I et al.: The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. (1998) 273:32347–32352.
  • KAFIENAH W, BROMME D, BUTTLE DJ, CROUCHER LJ, HOLLANDER AP: Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem. J. (1998) 331:727–732.
  • ••Very important paper that describes theunique function of cathepsin K against type I and II collagen fibrils.
  • GOLDIE I, NACHEMSON A: Synovial pH in rheumatoid knee-joints. I. The effect of synovectomy. Acta Orthop. Scand. (1969) 40:634–641.
  • LEVICK JR: Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure. J. Rheumatol. (1990) 17:579–582.
  • ANDERSSON SE, LEXMULLER K, JOHANSSON A, EKSTROM GM: Tissue and intracellular pH in normal periarticular soft tissue and during different phases of antigen induced arthritis in the rat. Rheumatol. (1999) 26:2018–2024.
  • TORTORELLA MD, BURN TC, PRATTA MA et al.: Purification and cloning of aggrecanase-1: a member of the ADAMs family of proteins. Science (1999) 284:164–1666.
  • ABBASZADE I, LIU RQ, YANG F et al.:Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. I Biol. Chem. (1999) 274:23443–23450.
  • ARNER EC, HUGHES CE, DECICCO CP, CATERSON B, TORTORELLA MD: Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthr. Cartil (1998) 6:214–228.
  • BUTTLE DJ, HANDLEY CJ, ILIC MZ, SAKLATVALA J, MURATA M, BARRETT AJ: Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases. Evidence for two converging pathways of chondrocyte-mediated proteoglycan degradation. Arthritis Rheum. (1993) 36:1709–1717.
  • MCDONNELL J, LOBNER JM, KNIGHT WB et al.: Comparison of the proteoglycanolytic activities of human leukocyte elastase and human cathepsin G in vitro and in vivo. Connect. Tissue Res. (1993) 30:1–9.
  • HOU WS, LI Z, BUTTNER FH, BARTNIK E, BROMME D: Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol. Chem. (2003) 384:891–897.
  • MORT JS, MAGNY MC, LEE ER: Cathepsin B: an alternative protease for the generation of an aggrecan Metalloproteinase' cleavage neoepitope. Biochem. J. (1998) 335:491–494.
  • HERRING GM: The organic matrix of bone. In: The Biochemistry and Physiology of Bone (Volume I, 2nd Edition). GH Bourne (Ed.), Academic Press, New York, NY, USA (1972):127–189.
  • MARKS SC ODGREN PR: Structure and development of the skeleton. In: Principles of Bone Biology (Volume I, 2nd Edition). JP B LG R GA Rodan (Eds), Academic Press, San Diego, CA, USA (2002):3–15.
  • ••Good review of basic bone biology.
  • BLAIR HC, ATHANASOU NA: Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol. (2004) 19:189–199.
  • EVERTS V, DELAISSE JM, KORPER W,BEERTSEN W: Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J. Bone Miner. Res. (1998) 13:1420–1430.
  • EVERTS V, DELAISSE JM, KORPER W: The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J. Bone Miner Res. (2002) 17:77–90.
  • PETTIT AR, THOMAS R: Dendritic cells:the driving force behind autoimmunity in rheumatoid arthritis? Immunol. Cell Biol. (1999) 77:420–427.
  • NAKAGAWA TY, BRISSETTE WH, LIRA PD et al: Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity (1999) 10:207–217.
  • HONEY K, RUDENSKY AY: Lysosomalcysteine proteases regulate antigen presentation. Nat. Rev Immunol. (2003) 3:472–482.
  • ABRAHAMSON M, ALVAREZ-FERNANDEZ M, NATHANSON CM: Cystatins. Biochem. Soc. Symp. (2003) 70:179–199.
  • LEROY V, THURAIRATNAM S: Cathepsin S inhibitors. Expert Opin. Ther. Patents (2004) 14:301–311.
  • BROMME D, KALETA J: Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Dec. (2002) 8:1639–1658.
  • YAMASHITA DS, SMITH WW, ZHAO B et al.: Structure and design of potent and selective cathepsin K inhibitors. J. Am. Chem. Soc. (1997) 119:11351–11352.
  • LEUNG D, ABBENANTE G, FAIRLIE DP: Protease inhibitors: current status and future prospects. J. Med. Chem. (2000) 43:305–341.
  • OTTO HH, SCHIRMEISTER T: Cysteine proteases and their inhibitors. Chem. Rev (1997) 97:133–171.
  • CLOSE DR: Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. (2001) 603662-iii67.
  • KEYSTONE E: Treatments no longer in development for rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61:ii43-ii45.
  • ESSER RE, WATTS LM, ANGELO RA, THORNBURG LP, PRIOR JJ, PALMER JT: The effects of fluoromethyl ketone inhibitors of cathepsin B on adjuvant induced arthritis. I Rheumatol (1993) 20:1176–1183.
  • BIROC SL, HUMMEL K et al: Cysteine protease activity is up-regulated in inflamed ankle joints of rats with adjuvant-induced arthritis and decreases with in vivo administration of a vinyl sulfone cysteine protease inhibitor. Arthritis. Rheum. (2001) 44:703–711.
  • RANADE VV, HOLLINGER MA: Drug delivery systems (2nd Edition). CRC Press, Boca Raton, FL, USA (2004).
  • WITKOP B: Paul Ehrlich and his magic bullets-revisited. Proc. Am. Philos. Soc. (1999) 143:540–557.
  • WALLIS WJ, SIMKIN PA, NELP WB: Protein traffic in human synovial effusion. Arthritis Rheum. (1987) 30:57–63.
  • LEVICK JR: Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum. (1981) 24:1550–1560.
  • KUSHNER I, SOMERVILLE JA: Permeability of human synovial membrane to plasma proteins. Relationship to molecular size and inflammation. Arthritis Rheum. (1971) 14:560–570.
  • ALBUQUERQUE M, LIMA JP: Articular lymphoscintigraphy in human knees using radiolabeled dextran. Lymphology (1990) 23:215–218.
  • WILKINSON LS, EDWARDS JC: Demonstration of lymphatics in human synovial tissue. Rheumatol Int. (1991) 11:151–155.
  • SEYMOUR LW: Passive tumor targeting ofsoluble macromoleculaes and drug conjugates. Grit. Rev Ther. Drug Carrier Syst. (1992) 9:135–187.
  • MATSUMURA Y, MAEDA H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. (1986) 46:6387–6392.
  • •Pioneer work on the EPR effect.
  • ARCURI C, SORIO R, TOGNON G et al.: A Phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma. Tumori (2004) 90:556–561.
  • MATSUMURA Y, HAMAGUCHI T, URA T et al: Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. .1 Cancer (2004) 91:1775–1781.
  • THOMSON AH, VASEY PA, MURRAY LS et al: Population pharmacokinetics in Phase I drug development: a Phase I study of PK1 in patients with solid tumours. BE J. Cancer (1999) 81:99–107.
  • WANG D, MILLER SC, SIMA M et al:The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. Pharm. Res. (2004) 21:1741–1749.
  • ANDERSON B, WANG D, MILLER SC, SIMA M, KOPECKOVA P, KOPECEK J: A novel macromolecular system to image and therapeutically target inflammatory disease in or near bone. J. Bone Mther. Res. (2004) 19:S474.
  • TIMOFEEVSKI SL, PANARIN EF, VINOGRADOV OL, NEZHENTSEV MV: Anti-inflammatory and antishock water-soluble polyesters of glucocorticoids with low level systemic toxicity. Pharm. Res. (1996) 13:476–480.
  • METSELAAR JM, WAUBEN MH, WAGENAAR-HILBERS JP, BOERMAN OC, STORM G: Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. (2003) 48:2059–2066.
  • WATERHOUSE DN, TARDI PG, MAYER LD, BALLY MB: A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Sal: (2001) 24:903–920.
  • FIEHN C, MULLER-LADNER U, GAYS et al.: Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (2004) 43:1097–1105.
  • TOGL-LEIMULLER A, EGGER G, PORTA S: Albumin as one-way transport vehicle into sites of inflammation. Exp. Pathol (1986) 30:91–96.
  • LAUFFER RB, PARMELEE DJ, DUNHAM SU et al: MS-325: albumin-targeted contrast agent for MR angiography. Radiology (1998) 207:529–538.
  • GRIST TM, KOROSEC FR, PETERS DC et al.: Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology (1998) 207:539–544.
  • DENNIS MS, ZHANG M, MENG YG et al.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. (2002) 277:35035–35043.
  • ROZMAN B: Clinical pharmacokinetics ofleflunomide. Clin. Pharmacokinet. (2002) 41:421–430.
  • FALCHUK KH, GOETZL EJ, KULKA JP: Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis. Am. J. Med. (1970) 49:223–231.
  • GEBOREK P, SAXNE T, PETTERSSON H, WOLLHEIM FA: Synovial fluid acidosis correlates with radiological joint destruction in rheumatoid arthritis knee joints. J. Rheumatol. (1989) 16:468–472.
  • FARR M, GARVEY K, BOLD AM, KENDALL MJ, BACON PA: Significance of the hydrogen ion concentration in synovial fluid in rheumatoid arthritis. Clim Exp. Rheumatol (1985) 3:99–104.
  • NORDSTROM T, SHRODE LD, ROTSTEIN OD et al.: Chronic extracellular acidosis induces plasmalemmal vacuolar type FP ATPase activity in osteoclasts. J. Biol. Chem. (1997) 272:6354–6360.
  • WARD TT, STEIGBIGEL RT: Acidosis of synovial fluid correlates with synovial fluid leukocytosis. Am. J. Med. (1978) 64:933–936.
  • ZHAO R, GAO F, HANSCOM M, GOLDMAN ID: A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier. Clim Cancer Res. (2004) 10:718–727.
  • GREENFIELD RS, KANEKO T, DAUES A et al: Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. (1990) 50:6600–6607.
  • DRUMMOND DC, ZIGNANI M, LEROUX J: Current status of pH-sensitive liposomes in drug delivery. Frog. Lipid Res. (2000) 39:409–460.
  • ••Very informative review on pH-sensitiveliposomes.
  • DRUMMOND DC, DALEKE DL: Synthesis and characterization of N-acylated, pH-sensitive 'caged' aminophospholipids. Chem. Phys. Lipids (1995) 75:27–41.
  • GERASIMOV OV, SCHWAN A, THOMPSON DH: Acid-catalyzed plasmenylcholine hydrolysis and its effect on bilayer permeability: a quantitative study. Biochim. Biophys. Acta. (1997) 1324:200–214.
  • MARTIN II, RUYSSCHAERT J, EPAND RIVI: Role of the N-terminal peptides of viral envelope proteins in membrane fusion. Adv. Drug Deify. Rev. (1999) 38:233–255.
  • PLANK C, ZAUNER W, WAGNER E: Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv. Drug Deify. Rev (1998) 34:21–35.
  • ALLEN TM, MARTIN FJ: Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. (2004) 31:5–15.
  • LEE ES, NA K, BAE YH: Super pH-sensitive multifunctional polymeric micelle. Nano. Lett. (2005) 5:325–329.
  • LEE ES, NA K, BAE YH: Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release (2005) 103:405–418.
  • OISHI M, NAGATSUGI F, SASAKI S, NAGASAKI Y, KATAOKA K: Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. Chembiochem. (2005) 6:718–725.
  • OISHI M, NAGASAKI Y, ITAKA K, NISHIYAMA N, KATAOKA K: Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. (2005) 127:1624–1625.
  • GILLIES ER, FRECHET JM: pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug. Chem. (2005) 16:361–368.
  • DROBNIK J, RYPAEK F: Soluble synthetic polymers in biological systems. Adv. Polym. Sri. (1984) 57:1–50.
  • KOPECEK J, KOPECKOVA P, MINKO T, LU Z: HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. Pharm. Biopharm. (2000) 50:61–81.
  • ••Very good review on HPMA copolymerdrug delivery systems.
  • WANG D, DUSIK K, KOPECKOVA P, DUSIOVA-SMRKOVA M, KOPECEK J: Novel aromatic azo containing pH sensitive hydrogels: synthesis and characterization. Macromolecules (2002) 35:7791–7803.
  • MARIS B, VERHEYDEN L, VAN REETH K et al.: Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. Int. J. Pharm. (2001) 213:143–152.
  • RAPP M, GIRAUD I, MAURIZIS JC, MADELMONT JC: Synthesis and pharmacokinetic profile of a quaternary ammonium derivative of chlorambucil, a potential anticancer drug for the chemotherapy of chondrosarcoma. Bioorg. Med. Chem. (2003) 11:5007–5012.
  • RAPP M, GIRAUD I, MAURIZIS JC, GALMIER MJ, MADELMONT JC: Synthesis and in vivo biodisposition of [14Q-quaternary ammonium-melphalan conjugate, a potential cartilage-targeted alkylating drug. Bioconjug. Chem. (2003) 14:500–506.
  • VAN OOTEGHAM SP, SMITH RG, DAVES GD Jr et al.: Iodo-bis(quaternary ammonium) salts. Potential cartilage-selective X-ray contrast agents../. Med. Chem. (1976) 19:1349–1352.
  • NORI A, JENSEN KD, TIJERINA M, KOPECKOVA P, KOPECEK J: Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells. Bioconjug. Chem. (2003) 14:44–50.
  • LAJEUNESSE D: The role of bone in the treatment of osteoarthritis. Osteoarthr. Garth. (2004) 12:S34–38.
  • WANG D, SIMA M, KOPECKOVA P, KOPECEK J: Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug. Chem. (2003) 14:853–859.
  • WANG D, KOPECKOVA P, KOPECEK J: Bone-targeted macromolecular therapeutics. Adv. Drug Deify. Rev. (2005) 57:1049–1076.
  • ••Very important review includingsuggestions for future development of bone-targeting drug delivery.
  • PARALKAR VM, BOROVECKI F, KE HZ et al.: An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc. Nati Acad. Sci. USA (2003) 100:6736–4049.
  • HAGINO H, KURAOKA M, KAMEYAMA Y, OKANO T, TESHIMA R: Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone (2005) 36:444–453.
  • WANG D, PECHAR M, LI W, KOPECKOVA P, BROMME D, KOPECEK J: Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry (2002) 41:8849–8859.
  • KOPECEK J: Targetable polymeric anticancer drugs. Temporal control of drug activity. Ann. NY Acad. Sci. (1991) 618:335–344.
  • DUNCAN R: The dawning era of polymer therapeutics. Nat. Rev Drug Discov. (2003) 2:347–360.
  • •A good general review on polymer therapeutics.
  • DUBOWCHIK GM, FIRESTONE RA: Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. (1998) 8:3341–3346.
  • DUBOWCHIK GM, MOSURE K, KNIPE JO, FIRESTONE RA: Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg. Med. Chem. Lett. (1998) 8:3347–3352.
  • TOKI BE, CERVENY CG, WAHL AF, SENTER PD: Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. I Org. Chem. (2002) 67:1866–1872.

Websites

  • http://www.arthritis.orgiresources/gettingstartedidefaultasp Website of Arthritis Foundation.
  • ••A valuable source of all types of generalInformation concerning arthritis.
  • http://www.merck.cominewsroomivioxx_withdrawa Y Website of Merck regarding the withdrawal of Vioxx.
  • http://www.bextra.com/Website provided by Pfizer for information related to Bextra.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.